Polyphor, Boehringer Ingelheim deal

Polyphor said Boehringer Ingelheim decided to enter the next stage of a June 2012 deal under which the companies partnered to use Polyphor's MacroFinder drug discovery technology to identify and optimize macrocyclic molecules against undisclosed targets selected by Boehringer. Polyphor said the hit identification stage was "successful" and the partners will to move forward to generate candidates suitable for preclinical development. The decision triggered an undisclosed milestone payment to Polyphor. Boehringer is responsible for development and commercialization of any candidates under the deal. Polyphor receives research funding from Boehringer and is eligible for milestones and royalties (see BioCentury, June 18, 2012). ...